Related Sciences - Short - TM.png

Discovering medicines
that are most likely to work

Related Sciences (RS) is a venture creation firm founded to discover new medicines for diseases with major unmet needs. Leveraging innovations from the past 10+ years of biotech company creation, we are building a scalable, data-driven platform for translating promising basic science into valuable drug candidates with the greatest possible chances of working safely and effectively in patients.

RS was founded by a team of life sciences company creators, investors, researchers, data scientists, and operators, and is backed by a luminary group of investors. 

Focusing on human evidence for human diseases

To identify the most promising drug discovery opportunities, our platform integrates multiple sources of public and proprietary data to find patient populations that are poorly served by current and emerging therapies, and well-positioned to benefit from new scientific advancements. We then compile human causal evidence from genetics and clinical data in order to uncover and prioritize therapeutic targets with the strongest links to disease and the greatest probability of safe and meaningful impact for patients.

Helping scientists help humans

To validate our science and develop breakthrough therapeutic hypotheses we build collaborative teams of scientific leaders from diverse disciplines and geographies, bringing together decades of innovative thinking in complementary areas of expertise. As promising drug programs emerge, we provide the significant resources needed to translate these discoveries into clinic-ready molecules, empowering our scientific partners to see their work positively impact patient care.


IMG_9393 - F crop.jpg

Adam Kolom

Adam Kolom is a biotech entrepreneur and private equity investor. Adam co-founded and led two of the world’s largest cancer immunotherapy research initiatives, and has overseen more than $850 million in biotechnology and healthcare investments. Prior to founding Related Sciences, Adam co-founded and served as Vice President of Sean Parker’s $250 million nonprofit, the Parker Institute for Cancer Immunotherapy (PICI), where he worked closely with Sean to design and assemble the Institute’s multi-center collaboration model and led more than 40 biopharma partnerships as the head of business development and intellectual property.  Before PICI, Adam was Managing Director of the Cancer Research Institute venture capital fund and global clinical trials program, a member of the healthcare private equity team at General Atlantic, a management consultant at McKinsey & Company, and an investment banker at UBS Investment Bank. Adam graduated with honors from the Wharton School at the University of Pennsylvania with a degree in finance and economics.


Jack Milwid

Jack Milwid is a scientist, entrepreneur, and investor. As a founder of biotech companies valued at over $5B, Jack has led R&D teams, invented platform technologies, and set strategy in an effort to create the next generation of life-saving medicines for patients. Prior to founding Related Sciences, Jack was a Principal at Flagship Pioneering, where he was a founder of the cell and gene therapy company Sana Biotechnology (SANA), a founder and leader of R&D for the targeted gene therapy company Cobalt Biomedicine, and the founding head of strategy for the microbiome therapeutics company Kaleido Biosciences (KLDO). Before Flagship, Jack was an entrepreneur at Third Rock Ventures where he cofounded cancer neoantigen vaccine pioneer, Neon Therapeutics. Jack has a PhD in Health Sciences and Technology from Harvard and MIT.


Jeff Hammerbacher

Jeff Hammerbacher is a scientist, software developer, entrepreneur, and investor. Jeff has founded and led teams that have produced dozens of scientific publications with hundreds of citations per year, 3 of the world's most popular open source database systems, over 100 angel investments, and a public company with a market capitalization of several billion dollars. Prior to founding Related Sciences, Jeff was the Principal Investigator of Hammer Lab, a founder and the Chief Scientist of Cloudera, an Entrepreneur-in-Residence at Accel, the manager of the Data team at Facebook, and a quant at Bear Stearns. In addition to his work at Related Sciences, Jeff is an angel investor with Techammer and is a board member at Ciox and Cytel. Jeff has a bachelor's degree in Mathematics from Harvard University.

Building a
new class of biotech

To drive efficient, world-class drug discovery, we create and finance virtual biotech companies, each designed around an asset-centric corporate structure and a flexible staffing model. By leveraging integrated teams comprised of employees, academic thought leaders, drug discovery experts, CROs, and biopharmaceutical partners, we can flexibly access specialized expertise and deploy the best drug discovery strategies, from traditional wet lab research to cutting-edge computational approaches.